Skip to main content
ClinicalTrials.govrestricted

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

ClinicalTrials.gov study NCT03529084. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.

ShareScore

24/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
8
Access
0
Reuse readiness
0
Engagement
4

Topics

Dataset details

Repository
ClinicalTrials.gov
Published
February 11, 2026
License
IPD-UNDECIDED
DOI
clinicaltrials.gov/NCT03529084

Scored with release 0.9.0

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.